A5067606220- Immunotherapy and Immune Responses
- HIV Research and Treatment
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- T-cell and Retrovirus Studies
- vaccines and immunoinformatics approaches
- Multiple Myeloma Research and Treatments
- T-cell and B-cell Immunology
- HIV/AIDS drug development and treatment
- Animal Disease Management and Epidemiology
- CAR-T cell therapy research
- HIV/AIDS Research and Interventions
- Vector-Borne Animal Diseases
- Cancer Research and Treatments
- Protein Degradation and Inhibitors
- Virus-based gene therapy research
- Pancreatic and Hepatic Oncology Research
- Hepatitis B Virus Studies
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- Herpesvirus Infections and Treatments
- Cancer Treatment and Pharmacology
- Cytomegalovirus and herpesvirus research
- HER2/EGFR in Cancer Research
- Cancer therapeutics and mechanisms
St George's, University of London
2015-2024
Auckland City Hospital
2024
St George's Hospital
1999-2023
University of London
1996-2023
St George's Hospital
2005-2020
Royal Marsden Hospital
1999-2018
Imperial College London
1998-2018
Institute For Cancer Vaccine & Immunotherapy
2016
Hospital General Universitario Gregorio Marañón
2016
Creative Commons
2015
To establish the phenotype of human T-cell leukemia virus type 1 (HTLV-1)-infected cells in peripheral blood, polymerase chain reaction was used to detect and quantitate viral DNA subpopulations leukocytes obtained from patients with tropical spastic paraparesis asymptomatic carriers. HTLV-1 could not be detected blood mononuclear thoroughly depleted T lymphocytes (E- CD3-), nor it highly enriched populations B CD19+), monocytes CD14+), or natural killer CD16+). were strongly positive for...
The CD4 (or T4) surface antigen of human T lymphocytes is an important part the receptor for immunodeficiency virus (HIV). After binding to receptor, HIV may enter cell and induce formation syncytia. In attempt identify site more closely, monoclonal antibodies (Mab's) were tested their ability block infection in a syncytium assay, epitopes so identified mapped by antibody cross-blocking. that showed strong inhibition fell into two main families while third group Mab's blocked syncytia weakly...
Some cancer patients are immuno-compromised, and it has been long felt that immune-intervention is not compatible with standard chemotherapies. However, increasing evidence suggests chemotherapy drugs may stimulate beneficial changes in both the immune system tumour.We have assessed expression of human leucocyte antigen class 1 (HLA1) on tumour cells before after agents (cyclophosphamide, oxaliplatin or gemcitabine). In addition, we show chemotherapy-stressed release cytokines enhance...
To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma.Twenty-four were treated a dose-escalating regimen oral CC-4047. Clinical responses adverse identified, peripheral T-cell subsets, serum cytokines, proangiogenic factors evaluated.CC-4047 was tolerated no serious nonhematologic events. All eligible for analysis. Toxicity criteria during initial 4 weeks study used to define maximum-tolerated...
The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties. Second generation analogues are distinct compounds enhanced therapeutic potential. Although these beginning to enter trials for the treatment cancer there is very little information regarding activity clinically relevant compounds. Furthermore, it not known how various immunomodulatory activities relate activity. In this study we assessed from both IMiD and SelCID classes using a novel in vitro...
High-grade glioma is one of the most aggressive cancers in adult humans and long-term survival rates are very low as standard treatments for remain largely unsuccessful. Cannabinoids have been shown to specifically inhibit growth well neutralize oncogenic processes such angiogenesis. In an attempt improve treatment outcome, we investigated effect Δ(9)-tetrahydrocannabinol (THC) cannabidiol (CBD) both alone combination with radiotherapy a number cell lines (T98G, U87MG, GL261). were used two...
Abstract Thalidomide and its novel T cell costimulatory analogs (immunomodulatory drugs) are currently being assessed in the treatment of patients with advanced cancer. However, neither tumor-specific costimulation nor effective antitumor activity has been demonstrated vivo. In this study, we ability an immunomodulatory drug (CC-4047/ACTIMID) to prime a immune response following tumor vaccination. We found that presence CC-4047 during priming phase strongly enhanced immunity vaccinated...
Summary Thalidomide (Thd) is clinically useful in a number of conditions where its efficacy probably related to anti-TNF-α activity. More recently, Thd has also been shown co-stimulate T cells and second generation co-stimulatory (IMiD™) analogues are currently being assessed the treatment cancer patients. However, contrast their known suppressive effects during inflammatory stimuli, Thd/IMiDs on TNF-α TNF receptors (TNFRs) cell co-stimulation not known. We sought determine effect Thd, two...